Financial reports
10-Q
2017 Q3
Quarterly report
13 Nov 17
10-Q
2017 Q2
Quarterly report
14 Aug 17
10-Q
2017 Q1
Quarterly report
9 May 17
10-K/A
2016 FY
Annual report (amended)
28 Apr 17
10-K
2016 FY
Annual report
31 Mar 17
10-Q
2016 Q3
Quarterly report
9 Nov 16
10-Q
2016 Q2
Quarterly report
9 Aug 16
10-Q
2016 Q1
Quarterly report
10 May 16
10-K/A
2015 FY
Annual report (amended)
29 Apr 16
10-K
2015 FY
Annual report
14 Mar 16
Current reports
8-K
Completion of Acquisition or Disposition of Assets
31 Jan 18
8-K
Repros Announces Negative Opinion From the EMA for Enclomiphene
26 Jan 18
8-K
Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency
15 Dec 17
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Dec 17
8-K
Repros Therapeutics Inc.® Announces Acquisition by Allergan plc
12 Dec 17
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Nov 17
8-K
Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results
13 Nov 17
8-K
Departure of Directors or Certain Officers
13 Oct 17
8-K
Submission of Matters to a Vote of Security Holders
15 Sep 17
8-K
REPROS THERAPEUTICS Corporate Presentation September 2017 Dedicated to Treating Male and Female Reproductive Disorders
11 Sep 17
Registration and prospectus
15-12B
Securities registration termination
9 Feb 18
25-NSE
Exchange delisting
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
POS AM
Prospectus update (post-effective amendment)
31 Jan 18
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 18
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 18
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 18
Proxies
DEF 14A
Definitive proxy
15 Aug 17
DEF 14A
Definitive proxy
24 May 16
DEF 14A
Definitive proxy
16 Apr 15
DEFA14A
Additional proxy soliciting materials
13 Apr 15
DEF 14A
Definitive proxy
29 Apr 14
DEF 14A
Definitive proxy
29 Apr 13
DEF 14A
Definitive proxy
27 Apr 12
DEF 14A
Definitive proxy
15 Apr 11
DEF 14A
Definitive proxy
6 Apr 10
PRE 14A
Preliminary proxy
25 Mar 10
Other
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
6 Feb 18
EFFECT
Notice of effectiveness
4 Aug 17
CORRESP
Correspondence with SEC
1 Aug 17
UPLOAD
Letter from SEC
31 Jul 17
EFFECT
Notice of effectiveness
23 Jun 16
EFFECT
Notice of effectiveness
24 Jul 14
Ownership
SC 13G/A
Repros Therapeutics Inc.
14 Feb 19
SC 13G/A
Repros Therapeutics Inc.
13 Feb 18
4
Katherine Anderson
31 Jan 18
4
Michael Wyllie
31 Jan 18
4
PATRICK FOURTEAU
31 Jan 18
4
Saira Ramasastry
31 Jan 18
4
DANIEL F CAIN
31 Jan 18
4
Nola E Masterson
31 Jan 18
SC 13G
Repros Therapeutics Inc.
2 Jan 18
SC 13G/A
Repros Therapeutics Inc.
2 Jan 18